Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Cells ; 13(16)2024 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-39195232

RESUMEN

From birth to adulthood, the mammalian heart grows primarily through increasing cardiomyocyte (CM) size, which is known as maturational hypertrophic growth. The Hippo-YAP signaling pathway is well known for regulating heart development and regeneration, but its roles in CM maturational hypertrophy have not been clearly addressed. Vestigial-like 4 (VGLL4) is a crucial component of the Hippo-YAP pathway, and it functions as a suppressor of YAP/TAZ, the terminal transcriptional effectors of this signaling pathway. To develop an in vitro model for studying CM maturational hypertrophy, we compared the biological effects of T3 (triiodothyronine), Dex (dexamethasone), and T3/Dex in cultured neonatal rat ventricular myocytes (NRVMs). The T3/Dex combination treatment stimulated greater maturational hypertrophy than either the T3 or Dex single treatment. Using T3/Dex treatment of NRVMs as an in vitro model, we found that activation of VGLL4 suppressed CM maturational hypertrophy. In the postnatal heart, activation of VGLL4 suppressed heart growth, impaired heart function, and decreased CM size. On the molecular level, activation of VGLL4 inhibited the PI3K-AKT pathway, and disrupting VGLL4 and TEAD interaction abolished this inhibition. In conclusion, our data suggest that VGLL4 suppresses CM maturational hypertrophy by inhibiting the YAP/TAZ-TEAD complex and its downstream activation of the PI3K-AKT pathway.


Asunto(s)
Cardiomegalia , Miocitos Cardíacos , Factores de Transcripción , Animales , Ratas , Cardiomegalia/metabolismo , Cardiomegalia/patología , Células Cultivadas , Dexametasona/farmacología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/efectos de los fármacos , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Factores de Transcripción/metabolismo , Triyodotironina/farmacología , Proteínas Señalizadoras YAP/metabolismo
2.
Life Sci Alliance ; 3(1)2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31843959

RESUMEN

Myocardial recovery from ischemia-reperfusion (IR) is shaped by the interaction of many signaling pathways and tissue repair processes, including the innate immune response. We and others previously showed that sustained expression of the transcriptional co-activator yes-associated protein (YAP) improves survival and myocardial outcome after myocardial infarction. Here, we asked whether transient YAP expression would improve myocardial outcome after IR injury. After IR, we transiently activated YAP in the myocardium with modified mRNA encoding a constitutively active form of YAP (aYAP modRNA). Histological studies 2 d after IR showed that aYAP modRNA reduced cardiomyocyte (CM) necrosis and neutrophil infiltration. 4 wk after IR, aYAP modRNA-treated mice had better heart function as well as reduced scar size and hypertrophic remodeling. In cultured neonatal and adult CMs, YAP attenuated H2O2- or LPS-induced CM necrosis. TLR signaling pathway components important for innate immune responses were suppressed by YAP/TEAD1. In summary, our findings demonstrate that aYAP modRNA treatment reduces CM necrosis, cardiac inflammation, and hypertrophic remodeling after IR stress.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/administración & dosificación , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/etiología , Daño por Reperfusión Miocárdica/complicaciones , Miocarditis/tratamiento farmacológico , Miocarditis/etiología , ARN Mensajero/administración & dosificación , Factores de Transcripción/administración & dosificación , Proteínas Adaptadoras Transductoras de Señales/genética , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Modelos Animales de Enfermedad , Humanos , Inyecciones Intramusculares , Ratones , Ratones Endogámicos C57BL , Miocardio/inmunología , Miocitos Cardíacos/metabolismo , Infiltración Neutrófila/efectos de los fármacos , Edición de ARN , ARN Mensajero/genética , Factores de Transcripción/genética , Proteínas Señalizadoras YAP
3.
Oncotarget ; 8(3): 4837-4848, 2017 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-27902477

RESUMEN

Doxorubicin (adriamycin), an anthracycline antibiotic, is commonly used to treat many types of solid and hematological malignancies. Unfortunately, clinical usage of doxorubicin is limited due to the associated acute and chronic cardiotoxicity. Previous studies demonstrated that Astragalus polysaccharide (APS), the extracts of Astragalus membranaceus, had strong anti-tumor activities and anti-inflammatory effects. However, whether APS could mitigate chemotherapy-induced cardiotoxicity is unclear thus far. We used a doxorubicin-induced neonatal rat cardiomyocyte injury model and a mouse heart failure model to explore the function of APS. GFP-LC3 adenovirus-mediated autophagic vesicle assays, GFP and RFP tandemly tagged LC3 (tfLC3) assays and Western blot analyses were performed to analyze the cell function and cell signaling changes following APS treatment in cardiomyocytes. First, doxorubicin treatment led to C57BL/6J mouse heart failure and increased cardiomyocyte apoptosis, with a disturbed cell autophagic flux. Second, APS restored autophagy in doxorubicin-treated primary neonatal rat ventricular myocytes and in the doxorubicin-induced heart failure mouse model. Third, APS attenuated doxorubicin-induced heart injury by regulating the AMPK/mTOR pathway. The mTOR inhibitor rapamycin significantly abrogated the protective effect of APS. These results suggest that doxorubicin could induce heart failure by disturbing cardiomyocyte autophagic flux, which may cause excessive cell apoptosis. APS could restore normal autophagic flux, ameliorating doxorubicin-induced cardiotoxicity by regulating the AMPK/mTOR pathway.


Asunto(s)
Astragalus propinquus/química , Cardiotoxicidad/tratamiento farmacológico , Doxorrubicina/toxicidad , Insuficiencia Cardíaca/tratamiento farmacológico , Pruebas de Función Cardíaca/efectos de los fármacos , Miocitos Cardíacos/efectos de los fármacos , Polisacáridos/administración & dosificación , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Autofagia , Cardiotoxicidad/metabolismo , Cardiotoxicidad/fisiopatología , Células Cultivadas , Modelos Animales de Enfermedad , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/fisiopatología , Masculino , Ratones , Ratones Endogámicos C57BL , Miocitos Cardíacos/citología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Polisacáridos/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Serina-Treonina Quinasas TOR/metabolismo
4.
Dev Cell ; 39(4): 466-479, 2016 11 21.
Artículo en Inglés | MEDLINE | ID: mdl-27720608

RESUMEN

Binding of the transcriptional co-activator YAP with the transcription factor TEAD stimulates growth of the heart and other organs. YAP overexpression potently stimulates fetal cardiomyocyte (CM) proliferation, but YAP's mitogenic potency declines postnatally. While investigating factors that limit YAP's postnatal mitogenic activity, we found that the CM-enriched TEAD1 binding protein VGLL4 inhibits CM proliferation by inhibiting TEAD1-YAP interaction and by targeting TEAD1 for degradation. Importantly, VGLL4 acetylation at lysine 225 negatively regulated its binding to TEAD1. This developmentally regulated acetylation event critically governs postnatal heart growth, since overexpression of an acetylation-refractory VGLL4 mutant enhanced TEAD1 degradation, limited neonatal CM proliferation, and caused CM necrosis. Our study defines an acetylation-mediated, VGLL4-dependent switch that regulates TEAD stability and YAP-TEAD activity. These insights may improve targeted modulation of TEAD-YAP activity in applications from cardiac regeneration to cancer.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Corazón/crecimiento & desarrollo , Fosfoproteínas/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal , Factores de Transcripción/metabolismo , Acetilación , Envejecimiento/metabolismo , Secuencia de Aminoácidos , Animales , Animales Recién Nacidos , Proteínas de Ciclo Celular , Proliferación Celular , Proteínas de Unión al ADN/metabolismo , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/patología , Vía de Señalización Hippo , Humanos , Unión Proteica , Dominios Proteicos , Estabilidad Proteica , Ratas Wistar , Factores de Transcripción de Dominio TEA , Factores de Transcripción/química , Proteínas Señalizadoras YAP
5.
Org Biomol Chem ; 11(36): 5994-7, 2013 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-23925313

RESUMEN

Bicyclo[3.2.0]hept-2-enes undergo thermal rearrangement to norbornenes via diradical transition structures. The synthesis of exo-7-cyclopropylbicyclo[3.2.0]hept-2-ene has been achieved by cycloaddition of cyclopentadiene and cyclopropylketene, generated by treatment of cyclopropylacetyl chloride with triethylamine. A comparison of the cyclopropyl substituent effect with that of other C7 substituents provides experimental evidence of an electron-donating conjugative effect on the transient diradical transition structure in the thermal reaction of exo-7-cyclopropylbicyclo[3.2.0]hept-2-ene.


Asunto(s)
Compuestos Bicíclicos con Puentes/síntesis química , Ciclopropanos/síntesis química , Electrones , Compuestos Bicíclicos con Puentes/química , Ciclización , Ciclopropanos/química , Estructura Molecular
6.
J Org Chem ; 77(7): 3468-74, 2012 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-22420624

RESUMEN

cis,anti,cis-Tricyclo[7.4.0.0(2,8)]tridec-10-ene (13TCT) undergoes [1,3] sigmatropic rearrangements at 315 °C in the gas phase to the si product 1 and to the sr product 2 with si/sr = 2.1. The dominant thermal isomerization process, however, is epimerization at C8 to afford product 3. That stereomutation at C8 occurs 50% faster than the si and sr shifts combined.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA